cytochrome b561 family member D2Genealiases: 101F6 · TSCytb · TSP10 · XXcos-LUCA11.4
Q-omics provides the consensus-scored CYB561D2 profile across patient tissues and cancer cell-line models. CYB561D2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CYB561D2 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, CYB561D2 RNA expression shows 19,404 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, LIHC, and ACC as cancer lineages where CYB561D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB561D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB561D2 survival associations across molecular data types. CYB561D2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB561D2 RNA expression–survival associations across cancer types. High CYB561D2 expression shows unfavorable associations in KICH, LGG, LIHC, ACC and KIRC, but favorable associations in PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for CYB561D2 RNA expression.
This table summarizes CYB561D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CYB561D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB561D2 shows lower tumor expression in LUSC, KIRC and THCA and higher tumor expression in LIHC, BRCA and UCEC. The LIHC box plot shows higher CYB561D2 RNA expression in tumor versus normal tissue (log2 FC = +1.257, t-test p < 0.001).
This table shows molecular features associated with CYB561D2 in patient tissues and cancer cell lines. In patient samples, CYB561D2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYB561D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
